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Abstract The role of two residues within the catalytic domain
of CDC25Mm, a mouse ras-specific guanine nucleotide exchange
factor (GEF), was investigated by site-directed mutagenesis. The
function of the mutant proteins was tested in vivo in both a
Saccharomyces cerevisiae cdc25 complementation assay and in a
mammalian fos-luciferase assay, and in in vitro assays on human
and yeast Ras proteins. Mutants CDC25MmE1048K and
CDC25MmS1122V were shown to be (partly) inactive proteins,
similar to their yeast homologs. Mutant CDC25MmS1122A showed
higher nucleotide exchange activity than the wild type protein on
the basis of both in vitro and in vivo assays. Thus, alanine and
valine substitutions at position 1122 within the GEF catalytic
domain originate mutations with opposite biological properties,
indicating an important role for position 1122 in GEF function.
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1. Introduction
Ras proteins are small guanine nucleotide binding proteins
acting as molecular switches in signal transduction [1]. The
level of the active, GTP-bound form results from the balance
of the competing activity of GTPase activating proteins
(GAP) and guanine nucleotide exchange factors (GEF) [2].
The prototypes of ras-speci¢c GEFs are the product of the
yeast CDC25 gene [3] and its close homolog SDC25 [4], the
¢rst protein of this class for which a ras-speci¢c GEF activity
was shown [5]. In mammalian cells two ras-speci¢c GEF
classes have been identi¢ed. One class ^ whose cDNA was
originally isolated by functional complementation of a cdc25
mutant of Saccharomyces cerevisiae ^ has been called
CDC25Mm and is mostly brain-speci¢c [6,7]. Human and rat
CDC25Mm homologs have also been isolated [8,9]. The other
class ^ Sos-GEF ^ has been isolated on the basis of homology
with the Son of Sevenless gene of Drosophila melanogaster [10]
and is expressed ubiquitously. Both GEFs are large, multi-
domain proteins: despite their di¡erent structural organiza-
tion, the two catalytic domains are approximately 70% ho-
mologous. The di¡erences in structural organization re£ect
the involvement in di¡erent signal transduction pathways.
Sos has been shown to work downstream of tyrosine kinase
receptors [11,12], while CDC25Mm may interact with trimeric
G protein-coupled receptors [13,14]. More recently a role for
CDC25Mm in synaptic transmission and long-term memory
has been proposed [15]. CDC25Mm has been shown to respond
to calcium levels [16,17]. Deregulated expression of both GEF
classes has been shown to induce cell transformation in di¡er-
ent experimental systems [18,19].
Understanding the mechanism by which GEFs activate ras
is of paramount importance for unraveling the biochemical
basis of ras-mediated signal transduction [20]. Several recent
papers addressed the role played by ras residues in interaction
with GEF (see for instance [21^24]), while much less informa-
tion is available on GEF amino acids involved in the inter-
action with ras [25^27]. In order to gain information on struc-
ture-function relationships of GEF catalytic domain, we used
CDC25Mm as a model molecule. The properties of the mutant
proteins were scored by a combination of in vitro assays on
puri¢ed proteins and functional tests in both yeast and mam-
malian cells. We show that mutations in residue 1122 may
originate either a thermolabile ‘loss-of-function’ protein with
reduced guanine nucleotide exchange activity or a thermo-
stable ‘gain-of-function’ protein with enhanced guanine nu-
cleotide exchange activity, suggesting that this position plays
a role in GEF stability and function.
2. Materials and methods
2.1. Yeast strains, media, plasmids and genetic manipulations
The yeast strain used in this study is TC7 (MATK ade lys trp1 ura3
cdc25-1) [3]. Liquid and solid media were prepared as described [28].
Plasmid pCYM-1 [29] was used as a plasmid for expression of wild
type and mutant catalytic domains in both yeast and CHO ¢broblasts,
because genes cloned under the control of its SV40 promoter can be
expressed both in yeast and in mammalian cells. Yeast was trans-
formed using lithium acetate [30] without carrier DNA. For the com-
plementation assays, the cells were spread on two plates and allowed
to growth at 24‡C for 36 h. After this period one of the plates was
shifted to 37‡C and colony growth on both plates scored 72 h later.
The complete CDC25Mm protein was expressed in NIH3T3 cells using
the pcDNA3 plasmid (Invitrogen) under the control of the cytomeg-
alovirus promoter.
2.2. Site-directed mutagenesis
The 3P-terminal region of the wild type CDC25Mm gene (en-
coding residues 974^1260 of the mature protein) was cloned in the
pALTER vector (Promega). Site-directed mutagenesis was performed
according to the manufacturer’s instructions (‘Altered sites in vitro
mutagenesis system’, Promega). The primers used for mutagenesis
were: CDC25MmS1122V , 5P-AGATCACCTCCGTCATCAACCGCAG-
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3P ; CDC25MmS1122A , 5P-AGATCACCTCCGCCATCAACCGCAG-3P ;
CDC25MmE1048K , 5P-TTCCTTATGAAAAGTTCTTTGGCCA-3P ;
CDC25MmE1048A , 5P-TTCCTTATGAAGCGTTCTTTGGCCA-3P. The
mutant codons are shown in bold type. Each mutant gene was com-
pletely sequenced in order to con¢rm that only the desired single-
codon change had been introduced.
2.3. Transfections and determination of fos-luciferase activity
CHO and NIH3T3 ¢broblasts were routinely grown in Dulbecco’s
modi¢ed Eagle’s medium supplemented with 10% fetal calf serum, 100
U/ml penicillin, 100 Wg/ml streptomycin and 4 mM glutamine. Cells
were transfected with pCYM-1- or pcDNA3-derived plasmids by the
calcium phosphate method and cotransfected with 2 Wg of the ras-
responsive fos-luciferase plasmid [18,31]. In all transfection DNA was
bu¡ered to a total of 16 Wg with pCYM-1 or pcDNA3 plasmid as
appropriate. After transfection, cells were starved for 40 h in serum-
free medium supplemented with 4 Wg/ml transferrin and 1038 M so-
dium selenite and collected. Luciferase activity was assayed essentially
as described [18] and normalized to protein content.
2.4. Protein puri¢cation and enzyme assays
The catalytic domains (residues 974^1260) of all mutants were
cloned into pGEX2T vector (Pharmacia) as previously described for
the wild type protein [6]. Wild type and mutant fusion proteins be-
tween glutathione S-transferase (GST) and CDC25Mm97431260 ^ ca. 58
kDa ^ were puri¢ed by glutathione-Sepharose chromatography (Phar-
macia) as previously described [6,32]. Glutathione-Sepharose-bound
fusion proteins were cleaved with thrombin (Serva) and further puri-
¢ed by SourceQ (Pharmacia) chromatography essentially as described
[33,34]. Recombinant RAS2 and p21ras proteins were obtained either
from Escherichia coli strains harboring pGEX-derived plasmids as
described by Parrini et al. [35], or as described by Lenzen et al.
[34]. The dissociation rates of the Ras-labelled guanine nucleotide
complexes and the cold GDP to radioactively labelled GTP exchange
reactions on RAS2 or p21ras were measured by a nitrocellulose bind-
ing assay at 30‡C as described [32]. The synthesis of mantGDP and
the charging of the p21ras protein with mantGDP were performed as
described by Lenzen et al. [33]. The £uorescence measurements (ex-
citation wavelength 366 nm and emission wavelength 450 nm) were
performed at 20‡C. The dissociation rate of 100 nM of the
p21rasWmant nucleotide in 50 mM Tris-HCl, pH 7.6, 5 mM MgCl2
and 5 mM DTE was followed in time after addition of a 200-fold
excess of GDP and the indicated concentration of either the wild type
or the mutant CDC25Mm catalytic domain.
2.5. BIAcore
The BIAcore measurements were performed basically as described
elsewhere [36]. In short, the surface of a sensor chip CMS research
grade (Pharmacia) was activated and charged with anti-GST serum
(Pharmacia) as described by the producer. The proteins were diluted
in bu¡er C (10 mM Na-HEPES, pH 7.4, 150 mM NaCl, 5 mM MgCl2
and 0.005% Igepal) to the appropriate concentration and kept at 4‡C.
The chip lane was charged with GST-p21ras by passing 35 Wl of 1 WM
GST-p21rasWGDP at 5 Wl/min, then the protein was made nucleotide-
free by passing 40 mM EDTA in bu¡er C for 6 min. Subsequently,
GST-free CDC25Mm catalytic domain was injected at the indicated
concentration and its association to GST-p21ras measured as a change
in surface plasmon resonance in time. The dissociation of the complex
was studied by passing bu¡er C over the lane. At the end of the
measurement, the chip lane was recycled by passing 20 mM glycine,
pH 2.0, and subsequently 0.05% SDS (4 min each), followed by a new
charging with GST-p21ras, EDTA washing and a new binding experi-
ment. This way, the e¡ect of at least nine di¡erent concentrations ^ in
the range 2^150 nM ^ of wild type and mutant CDC25Mm catalytic
domains on the surface plasmon resonance were measured. The asso-
ciation and dissociation rate constants were calculated using the pro-
gram BIAlogue 2.1 (Pharmacia).
3. Results
3.1. E¡ects of CDC25Mm mutations in vivo
The in vivo e¡ect of di¡erent mutations on activity of
CDC25Mm catalytic domains was tested in the yeast S. cere-
visiae and mammalian ¢broblasts. Positions 1048 and 1122
were chosen for mutagenesis because they correspond to po-
sitions altered in two thermosensitive yeast mutants [37]. So
far no biochemical characterization of the mutant proteins is
available. The same positions were also mutated to alanine, an
amino acid introducing minimal conformational stress which
is often used to probe the role of atoms in a given amino acid
extending beyond the L-carbon [38]. All our data, with the
exception of results reported in Fig. 3, refer to the catalytic
domains.
The cdc25-1 yeast strain TC7 was transformed with expres-
sion vectors expressing the mutated CDC25Mm catalytic do-
mains. Mutant proteins CDC25MmS1122V and CDC25MmE1048K
were unable to complement the cdc25-1 mutation (i.e. the
ratio of colonies growing at 37‡C vs. 24‡C was 6 0.01). These
results indicate that the corresponding mutations play the
same role in both yeast and mammalian GEFs, despite the
fact that the two positions are not universally conserved in the
Ras-speci¢c GEFs so far identi¢ed. Mutants CDC25MmS1122A
and CDC25MmE1048A were functional in the yeast assay,
although the latter mutant complemented the cdc25 mutant
slightly less e⁄ciently. The ratio of colonies growing at 37‡C
vs. 24‡C for mutants CDC25MmS1122A , CDC25MmE1048A and wild
type was 0.86 þ 0.03, 0.71 þ 0.07 and 0.87 þ 0.2, respectively.
The catalytic domain of CDC25Mm has been shown to ac-
tivate a ras-responsive fos-luciferase reporter gene in vivo in
CHO ¢broblasts [14]. We have transiently cotransfected our
mutant constructs together with the fos-luciferase reporter
plasmid into CHO cells and compared the ability of the en-
coded mutant proteins to trans-activate the fos promoter with
that of the wild type molecule.
Fig. 1 indicates that mutant CDC25MmE1048K , unable to com-
plement the cdc25-1 strain, was also not able to signi¢cantly
activate the fos promoter. Mutants CDC25MmE1048A and
CDC25MmS1122V were both able to weakly stimulate fos-lucifer-
ase activity, although they behaved di¡erently in the yeast
complementation assay. CDC25MmS1122A ^ the only mutant
complementing the yeast cdc25-1 strain as e⁄ciently as the
wild type ^ displayed a ras-dependent luciferase activity sig-
ni¢cantly higher than the wild type molecule.
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Fig. 1. Ras-dependent luciferase expression by CDC25Mm in CHO
cells. CHO ¢broblasts were cotransfected with fos-luciferase plasmid
(2 Wg) and 3 Wg of pCYM plasmid or derivatives containing the
wild type or mutated CDC25Mm catalytic domain. Data are ex-
pressed as percentage of luciferase activity in cells transfected with
CDC25Mm. Average+standard deviation of at least two independent
experiments ^ each conducted in duplicate ^ is shown.
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3.2. E¡ects of CDC25Mm mutations on GEF activity in vitro
The catalytic domain of each CDC25Mm mutant was ex-
pressed in ^ and puri¢ed from ^ E. coli cells as GST-fusion
proteins. All the mutant fusion proteins could be puri¢ed
under the same conditions as the wild type and their electro-
phoretic mobility was indistinguishable from the wild type.
Mutant GST-CDC25MmS1122A was more soluble than wild
type, whereas the other mutant proteins, most notably GST-
CDC25MmE1048K and GST-CDC25MmE1048A , were less soluble
than wild type (data not shown).
Addition of 40 nM CDC25Mm97431260 strongly increased the
intrinsic GDP/GTP exchange rate on the p21rasWGDP com-
plex. In keeping with results obtained in yeast, mutants
CDC25MmS1122V and CDC25MmE1048K were catalytically inactive
at 30‡C when measured with the radioactive exchange assay
on both human p21ras (Fig. 2A) and yeast RAS2 proteins
(Fig. 2B). Mutant CDC25MmE1048A , which is functional in the
yeast assay and gives intermediate results in the fos-luciferase
assay, did not show any signi¢cant stimulation of guanine
nucleotide exchange on either Ras protein. Only the
CDC25MmS1122A mutant signi¢cantly stimulated the GDP to
[3H]GTP exchange on Ras proteins, possibly more e⁄ciently
than wild type. The reasons for the di¡erent behavior of the
CDC25MmE1048A mutant in vivo in the yeast complementation
assay and in vitro is unclear. Since equivalent results were
obtained with the both the human and yeast Ras proteins,
the di¡erent results obtained in vivo in yeast and in vitro
with puri¢ed proteins do not depend on species-speci¢c inter-
action of the mutant GEF with the Ras substrate. More likely
some stabilization in vivo of the mutant protein by cytosolic
yeast proteins is taking place. Similar results were obtained
when measuring the stimulatory action of these mutants on
rasW[3H]GDP and RAS2W[3H]GDP in the presence of an excess
of GDP (data not shown), consistent with the observation
that the nature of the associating nucleotide does not a¡ect
the exchange rate [36].
3.3. The S1122A mutation results in a ‘gain-of-function’ protein
Results reported in the previous sections suggested that the
S1122A mutation may originate a ‘gain-of-function’ protein.
Thus the properties of the CDC25MmS1122A and CDC25MmS1122V
mutants were examined in more detail.
The full length CDC25Mm molecule has been shown to ac-
tivate ras-dependent luciferase activity more e⁄ciently than
the catalytic domain [14], possibly because the 1260 amino
acid long molecule is more stable than the catalytic domain
alone (R. Zippel, personal communication). We thus investi-
gated whether the S1122A mutation a¡ected similarly the full
length GEF molecule. Dose-response curves were constructed
with plasmids expressing both the wild type and the
CDC25MmS1122A full length proteins. Both mutant and wild
type proteins showed dose-dependent fos-luciferase activity,
but the CDC25MmS1122A mutant had a signi¢cantly higher max-
imal activity than wild type, and reached the maximal value at
much lower plasmid concentration (Fig. 3).
The wild type and mutant catalytic domains were puri¢ed
free of the GST moieties by thrombin cleavage, as described
in Section 2. Di¡erent preparations of the same protein
showed variations in activity, most likely due to variations
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Fig. 3. Dosage dependence of wild type and S1122A mutant on fos-
luciferase activity in transfected NIH3T3 cells. NIH3T3 cells were
cotransfected with fos-luciferase plasmid (2 Wg) and either plasmid
pcDNA3 (white bars), or derivatives carrying the whole length wild
type CDC25Mm gene (hatched bars) or the corresponding
CDC25 MmS1122A mutant (black bars). Data are expressed as percent-
age of luciferase activity in cells transfected with 1 Wg CDC25Mm.
Average+standard deviation of at least two independent experiments
^ each conducted in duplicate ^ is shown.
Fig. 2. Stimulation of the GDP to [3H]GTP exchange reaction of p21rasWGDP (A) and RAS2WGDP (B) by the catalytic domains of CDC25Mm
and the mutants. 0.5 WM p21rasWGDP (A) and RAS2WGDP (B) were incubated at 30‡C in bu¡er A. The reaction was started by addition of a
25-fold excess of [3H]GTP over the RasWGDP complex as described in Section 2. Average + standard deviation of at least two independent ex-
periments ^ each conducted in duplicate ^ is shown for wild type and CDC25 MmS1122A . In order to avoid visual cluttering, standard deviations
for inactive mutant and Ras proteins alone are not shown; at each time point they were below 10%. Symbols are as follows: (U), intrinsic ex-
change; (a) CDC25Mm wild type; (E) CDC25 MmS1122V ; (b) CDC25 MmS1122A ; (O) CDC25 MmE1048K ; (F) CDC25 MmE1048A .
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in the duration of the puri¢cation and temperature £uctua-
tions that may occur for instance during cell extraction.
Dissociation assays were conducted at 20‡C, since at this
temperature the wild type does not display signi¢cant thermo-
sensitivity [36]. Interestingly, 50 nM of the thrombin-cleaved
catalytic domain of CDC25MmS1122A was able to stimulate the
dissociation of 100 nM RasWmGDP with a 2^4-fold higher rate
than wild-type CDC25Mm, whereas the CDC25MmS1122V was
nearly two-fold less active than wild type (in the presence of
CDC25Mm wild type, the dissociation rate constant was
0.00104 þ 0.00020 s31).
The puri¢ed thrombin-cleaved catalytic domains were then
analyzed with respect to temperature stability as depicted in
Fig. 4. The proteins were pre-incubated for 15 min at the
indicated temperatures and the residual GEF activity was as-
sayed at 20‡C after centrifugation. As observed earlier [36],
the wild type protein is thermolabile and loses most of its
activity after 15 min incubation at 40‡C (Fig. 4). Mutant
protein CDC25MmS1122V was signi¢cantly more thermosensitive
than wild type, since its activity was drastically reduced after
pre-incubation at 35‡C, in keeping with the fact that a valine
at the homologous position makes the yeast CDC25 protein
thermosensitive. In this particular experiment, after pre-incu-
bation at 25‡C, CDC25MmS1122V is approximately four times
less active than wild type, which indicates a larger di¡erence
than observed in the standard dissociation assay mentioned
above. This may be caused by a sensitivity of CDC25MmS1122V
towards pre-incubation and/or centrifugation. Interestingly,
mutant CDC25MmS1122A was shown to be much more thermo-
stable than wild type, since even after pre-incubation at 40‡C
nearly full GEF activity could be observed.
We decided to directly investigate quantitatively the binding
of CDC25MmS1122A and CDC25MmS1122V mutant proteins to nu-
cleotide-free GST-coupled ras by BIAcore experiments. Anal-
ysis of the association and dissociation curves at di¡erent
concentrations of both mutant proteins allowed us to calcu-
late kon, koff and KD. The results are summarized in Table 1.
Equilibrium constants for the wild type and the
CDC25MmS1122A mutant proteins were similar, despite the
more than three times di¡erences in GEF speci¢c activity,
while CDC25MmS1122V , in contrast displayed an increased KD.
4. Discussion
Up to now, the interactions between Ras proteins and their
GEFs have been analyzed by mutational studies concerning
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Table 1
Equilibrium and rate constants derived from BIAcore experiments
for wild type and mutant CDC25Mm catalytic domains
Protein kon
(105 M31 s31)
koff
(1034 s31)
KD
(nM)
CDC25Mm 4.4 þ 1.9 5.0 þ 0.3 1.1
CDC25 MmS1122A 4.6 þ 2.3 3.5 þ 1.0 0.8
CDC25 MmS1122V 2.5 þ 0.5 6.8 þ 3.5 2.7
Fig. 4. Temperature dependence of CDC25Mm wild type, CDC25 MmS1122V and CDC25 MmS1122A activity. CDC25Mm proteins (25 nM) were incu-
bated with RasWmantGDP (100 nM) for 15 min at 25‡C (A), 30‡C (B), 35‡C (C) or 40‡C (D), cooled down on ice and centrifuged. The super-
natant was assayed for GEF activity as described in Section 2 by adding 20 WM GDP. Depicted is the £uorescence decrease following dissocia-
tion of p21rasWmantGDP in the absence (U) or presence of CDC25Mm wild type (a), CDC25 MmS1122A (b) or CDC25 MmS1122V (E).
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mostly the substrate Ras. We analyzed the biochemical prop-
erties of mutant GEFs mapping at positions 1048 and 1122 ^
corresponding to positions mutated in two yeast cdc25 tem-
perature sensitive mutants ^ using both in vivo and in vitro
assays.
Mutation of glutamic acid 1048 to lysine leads to loss of
function. The mutant CDC25MmE1048K shows no activity in the
complementation assay, no signi¢cant stimulation of lucifer-
ase activity and no guanine nucleotide exchange activity in
vitro. Mutating the same residue to Ala appears to a¡ect
the function of CDC25Mm less drastically, as demonstrated
by the reduced, but signi¢cant activity of this mutant in the
in vivo experiments in both yeast and CHO ¢broblasts. How-
ever, the mutant does not show any in vitro guanine nucleo-
tide exchange activity. Lack of detectable biological activity in
the exchange and dissociation reaction in vitro was not the
result of the production of a grossly misfolded protein, since
the mutant CDC25MmE1048K protein was able to compete with
wild type CDC25Mm for p21ras binding, leading to a severely
reduced (43 þ 3%, average of two independent experiments)
guanine nucleotide exchange when added in a 10-fold excess
over wild type (data not shown). These seemingly contrasting
results could be explained by assuming that some cell pro-
tein(s) may have a stabilizing e¡ect on this mutant. This
may result in di¡erent sensitivities of the various in vivo
and in vitro assays, pointing out that careful characterization
of a mutant protein requires a combination of di¡erent com-
plementary approaches. In budding yeast a low level GEF
activity appears to be su⁄cient to support growth as indicated
by the low steady state levels and short half-life of the CDC25
protein [39]. This observation suggests that even protein with
a severe reduced activity may provide enough activity to sup-
port growth.
A somehow complementary situation was observed with
mutant CDC25MmS1122V , which was inactive in the yeast com-
plementation assay but displayed intermediate levels of fos-
luciferase activity in transfected CHO cells, possibly re£ecting
di¡erent e⁄ciencies with which the SV40 promoter of the
pCYM plasmid drives transcription in the di¡erent hosts,
the requirement of di¡erent levels of active GEF to give a
detectable signal and/or the stabilizing e¡ect of interacting
proteins in each cell. These di¡erences may become more im-
portant as the proteins become less stable which is the case
with the CDC25MmS1122V mutant. In analogy to the yeast pro-
tein, mutation of serine 1122 to valine in the mammalian
CDC25Mm protein increased the thermosensitivity of the pro-
tein (Fig. 4). Interestingly, mutation of the serine 1122 to
alanine ^ present in the yeast wild type protein, as well as
in the highly homologous mouse GRF2-encoded protein [40]
^ increases activity and thermostability of the mammalian
GEF.
The opposite e¡ects brought about by the alanine and va-
line mutations at position 1122 are remarkable. On the basis
of the described in vitro and in vivo experiments the
CDC25MmS1122A mutant behaves as a ‘gain-of-function’ mutant
since it has higher fos-luciferase activity, is more thermostable
and more e⁄ciently catalyzes nucleotide dissociation from ras.
The latter e¡ect is well evident at 20‡C, where the puri¢ed
catalytic domains of CDC25MmS1122A and wild type are both
stable, implying that the 2^4-fold higher catalytic activity of
the mutant is not a consequence of an increased thermostabil-
ity. BIAcore analysis showed that mutation S1122A does not
a¡ect the interaction between nucleotide-free Ras and
CDC25Mm. Interestingly, in the recently published RasWSos
structure [41] it was shown that residue A877 (the Sos homo-
logue of CDC25Mm residue S1122) is located in an K-helix that
participates in the interaction with Ras. Although its neighbor
S876 interacts with Ras residue Q70 via a H-bond, A877 does
not seem to be involved in direct interaction, at least in the
nucleotide-free complex. Consequently, mutation S1122A is
more likely to (directly or indirectly) in£uence the stability
of the ternary complex RasWGXPWCDC25Mm and/or facilitate
conformational changes that occur during the exchange reac-
tion, e.g. the putative rate-limiting isomerization from a high
to a low nucleotide a⁄nity conformation [36]. Apart from the
homologous yeast CDC25 mutants, whose biochemical prop-
erties were not investigated, only one other mutant mapping
close to position 1122 was described [26]. This mutant was
generated in the human homolog of CDC25Mm and corre-
sponds to position 1130. This Arg to Ala mutation resulted
in a slightly thermosensitive protein, since it was able to com-
plement a temperature sensitive yeast cdc25 mutant at 37‡C
but not at 40‡C. The mutant retained the ability to bind Ras
proteins as determined by two hybrid analysis in S. cerevisiae.
The ¢nding that two independent mutations mapping within
the same 10 amino acid region gave temperature sensitive
phenotypes suggests that this region may play an important
role in GEF stability. Moreover, our ¢nding that mutation
S1122A results in a gain-of-function mutant, not only more
thermostable but also more catalytically active than wild type,
indicates that position 1122 may play a role not only in struc-
tural stability, but in catalysis as well.
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